Lancet ID Commentary to the G20 on behalf of the DRIVE-AB Steering Committee

I am pleased to say that a commentary to the G20 on behalf of the DRIVE-AB Steering Committee has now gone live in the Online First section of Lancet Infectious Diseases. The article is not Open Access so you’ll have to download it for yourself (link below).

The commentary summarises some of DRIVE-AB’s preliminary findings that are pertinent to the G20 discussions as this list of recommendations:

  • Immediately fill the gap of US$250 million per year in push funding; existing mechanisms require additional financing and are well suited for an immediate in-flow of extra financing
  • Implement market entry reward pilots to learn about the operationalisation of such models
  • Request that regional and global banking institutions (such as the European Investment Bank and the World Bank) examine potential novel financial instruments to support further antibacterial R&D funding
  • Establish a mechanism for multinational coordination and collaboration
  • Develop health technology assessment processes and rules of reimbursement to consider the resistance situation and capture antibiotic societal value

DRIVE-AB’s complete findings will be published and presented at the DRIVE-AB conference in Brussels on Sept 5–6, 2017. 

Best wishes and stayed tuned for further developments! –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust | Follow me on Twitter: @JohnRex_NewAbx

Upcoming events of note outside of the mainstream large meetings:

  • 10-11 July: FDA workshop on bacteriophage therapies
  • 19 July: FDA workshop on combination therapy for TB
  • 5-9 Sep: ASM-ESCMID conference on antibiotic R&D, including the CARB-X + GARDP Antibiotic Bootcamp
  • 13 Sep 2017 (DC): FDA-CDRH workshop on diagnostic devices for detecting antimicrobial susceptibility & resistance

Link to online article: http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(17)30404-8/abstract

Share

17 April 2023: FREE Masterclass from FDA / CARB-X wants you!

Dear All, Two quick items today. First, FDA have announced an Antimicrobial Drugs Advisory Committee on 17 April 2023 (9a-4.30p ET). The committee will “discuss new drug application (NDA) 216974, for sulbactam-durlobactam for injection, submitted by Entasis Therapeutics, Inc. The Applicant’s proposed indication is for the treatment of infections due to Acinetobacter baumannii-calcoaceticus complex including multidrug-resistant and

WHO 2023 Pipeline Update: Share Your Preclinical Antibacterial Projects!

Dear All, As you know, WHO updates their preclinical and clinical pipeline summaries at regular intervals. The most current reviews are summarized on https://amr.solutions/pathogens-and-pipelines/. These excellent summaries are invaluable for researchers of all types and are also used to inform policy work. There is now a call to for current information on antibacterial pre-clinical projects. Go here

PASTEUR: Sign a letter to make it happen this year!

Dear All, As all regular readers of this newsletter know, I think that creation of suitable Pull incentives by passage of the PASTEUR Act in the United States is THE key to building a vibrant pipeline of products to address the international problem of AMR. PASTEUR came very close to passage at the end of 2022 …

Scroll to Top